Recent Updates — SSII
SS Innovations International announced that its SSi Mantra surgical robotic system and SSi MantrAsana tele-surgeon console were showcased in successful telesurgeries during October 2026. At the European Association for Cardio-Thoracic Surgery Annual Meeting in Barcelona, Chairman and CEO Dr. Sudhir Srivastava performed a live remote cardiac procedure from Spain to India. Additionally, four robotic-assisted telesurgeries were demonstrated at the Society of Robotic Surgery India Conference in New Delhi. As of October 23, 2026, the company reported that a total of 205 telesurgeries have been performed using the SSi Mantra system. SS Innovations International develops innovative surgical robotic technologies to make robotic surgery affordable and accessible globally.
SS Innovations International submitted its response to a request for additional information from the U.S. Food and Drug Administration regarding its 510(k) application for the SSi Mantra surgical robotic system on October 5, 2026. The submission includes final data from an expanded human clinical study and a bridging study conducted in Colombia. The company anticipates the FDA will complete its review of the 510(k) submission in the first quarter of 2027. SS Innovations International develops innovative surgical robotic technologies to make robotic surgery affordable and accessible globally.
On October 9, 2026, SS Innovations International entered into a Securities Purchase Agreement and issued a secured convertible promissory note to an institutional investor for an aggregate purchase price of $20,000,000. The Note carries an original principal amount of $21,025,000, reflecting an original issue discount of $1,000,000 and transaction expenses of $25,000. It bears interest at 8.75% per annum compounded daily and matures thirty-six months after the closing date. The Note is secured by the Company's intellectual property and other assets, excluding its Indian subsidiary, and includes conversion features tied to market price thresholds. SS Innovations International operates in the technology sector.
SS Innovations International filed an 8-K to furnish an updated October 2026 investor presentation detailing its commercial progress in the surgical robotics sector. The filing highlights that the company generated approximately $42.5 million in revenue for the full year 2025, with gross margins expanding to 46%. As of September 2026, the SSi Mantra system has been installed at 218 hospitals across 12 countries, facilitating over 14,503 multi-specialty surgeries. The company also reported 195 completed telesurgeries and noted that its US FDA 510(k) review is anticipated to conclude in the first quarter of 2027. SS Innovations International develops advanced, affordable surgical robotic solutions.
SS Innovations International, Inc. announced that Sarah Romano ceased serving as its Chief Financial Officer effective August 21, 2026. The filing states that her departure was not the result of any disagreement with the Company regarding financial reporting, internal controls, operations, policies, or accounting practices. SS Innovations International operates in the information technology services industry.